Anlotinib Therapy in Patients With Advanced Lung Cancer.
NCT ID: NCT03940404
Last Updated: 2019-05-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1000 participants
OBSERVATIONAL
2019-05-31
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Subjects of the study: advanced Lung cancer.
Methods of the study:
This is a real world, prospective, Non-Interventional, Follow-up registration study.
Patients will get Anlotinib according to their condition and willingness. Anlotinib will give orally, once daily on days 1-14 of a 21-day cycle. After the procedure, regular follow up after every cycle.
End point:
Primary end point: progression-free survival (PFS). Secondary end points: overall survival (OS), disease control rate (DCR), overall response rate (ORR).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer
NCT06341530
Real World Observational Study of Pembrolizumab for Chinese Advanced NSCLC
NCT04153097
Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody
NCT03975036
Local Therapy in Advanced NSCLC With Non-progressive Disease (PD) After First Line Therapy
NCT03046316
Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors
NCT05460481
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
experiment
The patients whose treatment strategy containing anlotinib.
Anlotinib Hydrochloride
Anlotinib will give orally, once daily on days 1-14 of a 21-day cycle. Dose reduction is allowed.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anlotinib Hydrochloride
Anlotinib will give orally, once daily on days 1-14 of a 21-day cycle. Dose reduction is allowed.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients who had to have histologically and/or cytologically confirmed NSCLC that failed at least 2 kinds of systemic chemotherapy (third line or beyond), or who will obtain benefit from antiangiogenic therapy after investigator's assessment.
3. Eastern Cooperative Oncology Group performance status of 0-2.
Exclusion Criteria
2. Pregnant or lactating women.
3. Other patients who can't enroll after investigator's assessment.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cttq
INDUSTRY
First People's Hospital of Hangzhou
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shenglin Ma
Role: PRINCIPAL_INVESTIGATOR
First People's Hospital of Hangzhou
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
First People's Hospital of Hangzhou
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ALOT-LC1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.